Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 08 Oct, 16:00 UTC

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

science

Sources

• T2Viatris boosts pain drug portfolio with $1.7B buyout of PaciraBioPharma Dive / Healthcare Dive / MedTech Dive08 Oct, 16:00